GlassScriptPhysician profile
David James Cochran
NPI 1174050538
$3,696.24
in general payments reported to CMS, 2019-2025
20 companies · $909 in 2025
The $909 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,068 · 2021: $67.57 · 2022: $512 · 2023: $389 · 2024: $750 · 2025: $909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,048.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,428.06 | 2019-2024 | Rezum Generator, Ams 700, Ams 700 Cxr Rte Kit |
| Medtronic, INC. | $617.82 | 2022-2025 | Interstim |
| Axonics, INC. | $312.17 | 2023-2024 | Axonics, Bulkamid |
| Astellas Pharma US INC | $269.78 | 2022-2025 | Xtandi, Myrbetriq |
| Coloplast Corp | $231.22 | 2023-2025 | Altis |
| Laborie Medical Technologies Corp. | $152.57 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Dendreon Pharmaceuticals LLC | $127.21 | 2019 | |
| Pfizer INC. | $117.47 | 2023-2025 | |
| Teleflex LLC | $69.73 | 2022-2025 | Barrigel |
| Merck Sharp & Dohme LLC | $61.87 | 2021-2025 | Keytruda |
| Progenics Pharmaceuticals, INC. | $42.09 | 2023-2024 | Pylarify |
| Myriad Genetic Laboratories, INC. | $41.01 | 2024 | Myrisk |
| Accord Healthcare, INC. | $35.83 | 2025 | |
| Immunitybio, INC. | $34.86 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.76 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Civco Medical Instruments | $33.22 | 2025 | |
| Janssen Biotech, INC. | $28.29 | 2024 | Erleada |
| Myovant Sciences INC. | $21.46 | 2022 | |
| Endo Pharmaceuticals INC. | $20.58 | 2022 | |
| Sumitomo Pharma America, INC. | $17.24 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cochran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.